The First Batch Of Avifavir From COVID-19 Will Go To Hospitals In The Russian Federation On June 11

Table of contents:

The First Batch Of Avifavir From COVID-19 Will Go To Hospitals In The Russian Federation On June 11
The First Batch Of Avifavir From COVID-19 Will Go To Hospitals In The Russian Federation On June 11

Video: The First Batch Of Avifavir From COVID-19 Will Go To Hospitals In The Russian Federation On June 11

Отличия серверных жестких дисков от десктопных
Video: Russia to start using Avifavir as a Covid-19 treatment from June 2023, January
Anonim

The first batch of Avifavir from COVID-19 will go to hospitals in the Russian Federation on June 11

Earlier, the Russian Direct Investment Fund and the ChemRar group of companies announced the registration of a drug that reportedly showed its effectiveness in clinical trials against coronavirus.

The first batch of the drug
The first batch of the drug

Photo: chemrar.ru

According to the press service of ChemRar, Avifavir has been well studied, since 2014 it has been used in Japan against severe forms of influenza.

“Interim data from the clinical study of Avifavir confirm the high efficacy of the drug for the treatment of COVID-19. The final phase of the Avifavir clinical trial, approved by the Ministry of Health on May 21, with 330 patients, continues. The drug has demonstrated high efficiency according to the results of tests carried out by a number of leading medical and scientific centers, including the First Moscow State Medical University named after I.M. Sechenov, Moscow State University M.V. Lomonosov and others, "- said in the message of ChemRar.

According to Kirill Dmitriev, CEO of the Russian Direct Investment Fund, Afivavir is not only the first antiviral drug registered against coronavirus in Russia, but possibly the most promising anti-COVID-19 drug in the world. It was developed and tested in clinical trials in Russia in record time, which allowed it to become the first registered drug based on Favipiravir in the world."

Despite claims of proven effectiveness, Avifavir cannot be called a universal remedy for COVID-19, so it should not be used to treat pregnant women. This was announced during an online conference by Vladimir Chulanov, Deputy Director of the National Research Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation. According to him, the drug can have a so-called teratogenic effect, that is, cause violations of embryonic development.

The first consignments of Avifavir will be sent to Roszdravnadzor to receive a conclusion for putting into circulation in early June, and the first deliveries to Russian hospitals are expected on June 11 - at least 60 thousand courses of Avivavir.

Popular by topic